AG
LCTX icon

Artal Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Artal Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-743,407
Closed -$2.18M – 84
2015
Q2 		$2.18M Buy
743,407
+247,802
+50% +$961K 0.09% 64
2015
Q1 		$1.99M Buy
+495,605
New +$1.71M 0.09% 70

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IA
IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artal Group's LCTX Position: Q1 2018 in Review

Artal Group sold out of Lineage Cell Therapeutics (LCTX) in Q1 2018, closing a stake of 1,779,708 shares — an estimated $3.35M sold.

Artal Group first reported a position in LCTX in Q4 2014 and held it in 13 quarters. The position peaked at $6.37M in Q1 2015. 115 funds tracked by Wall St. Rank hold LCTX as of Q1 2018.

  • Artal Group reported no remaining Lineage Cell Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Artal Group sold 1,779,708 Lineage Cell Therapeutics shares in Q1 2018, an estimated $3.35M.
  • Artal Group first reported a position in Lineage Cell Therapeutics in Q4 2014 and held it in 13 quarters.
  • Artal Group's Lineage Cell Therapeutics position peaked at $6.37M in Q1 2015.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.